B

Basilea Pharmaceutica AG Allschwil
SWB:PK5

Watchlist Manager
Basilea Pharmaceutica AG Allschwil
SWB:PK5
Watchlist
Price: 57.6 EUR 1.41% Market Closed
Market Cap: 695.3m EUR

Wall Street
Price Targets

PK5 Price Targets Summary
Basilea Pharmaceutica AG Allschwil

There are no price targets for PK5.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Basilea Pharmaceutica AG Allschwil Competitors:
Price Targets
QURE
Uniqure NV
138% Upside
301207
Hualan Biological Bacterin Inc
1% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
10% Upside
1801
Innovent Biologics Inc
29% Upside
4974
Takara Bio Inc
44% Upside
RARE
Ultragenyx Pharmaceutical Inc
150% Upside
OPK
OPKO Health Inc
186% Upside
ZYME
Zymeworks Inc
29% Upside

Revenue
Forecast

Revenue Estimate
Basilea Pharmaceutica AG Allschwil

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG Allschwil's revenue is 9%. The projected CAGR for the next 4 years is 3%.

9%
Past Growth
3%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Basilea Pharmaceutica AG Allschwil

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's operating income for the next 4 years is -33%.

N/A
Past Growth
-33%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Basilea Pharmaceutica AG Allschwil

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's net income for the next 4 years is -36%.

N/A
Past Growth
-36%
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PK5's stock price target?
Not Available

PK5 doesn't have any price targets made by Wall Street professionals.

What is Basilea Pharmaceutica AG Allschwil's Revenue forecast?
Projected CAGR
3%

For the last 13 years the compound annual growth rate for Basilea Pharmaceutica AG Allschwil's revenue is 9%. The projected CAGR for the next 4 years is 3%.

What is Basilea Pharmaceutica AG Allschwil's Operating Income forecast?
Projected CAGR
-33%

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's operating income for the next 4 years is -33%.

What is Basilea Pharmaceutica AG Allschwil's Net Income forecast?
Projected CAGR
-36%

The compound annual growth rate of Basilea Pharmaceutica AG Allschwil's net income for the next 4 years is -36%.

Back to Top